Munger Mode rating: 3 out of 5 — Hold. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
Warren here, with Charlie looking over my shoulder. Abbott is one of those companies we've watched for half a century — it's been raising its dividend since before most fund managers were born, and it sells things that people need whether the economy is booming or busted: glucose sensors, heart devices, diagnostic tests, baby formula, and branded generic drugs in emerging markets. Abbott runs four businesses under one roof, and you can explain each to a bright twelve-year-old: 1. Medical Devices (~46% of sales, Q2 2026: $5.85B) — The crown jewel is FreeStyle Libre, a continuous glucose monitor (CGM) worn on the arm that replaced the finger-prick for millions of diabetics. Diabetes Care alone did $2.19B in the quarter, up 10%. The rest is cardiovascular hardware — pacemakers, electrophysiology catheters, stents, structural heart valves — largely acquired with St. Jude Medical in 2017.
Recent filings analysed: 8-K (2026-08-20), 10-Q (2026-07-28), 10-Q (2026-04-29), 8-K (2026-04-27).
Stock screener · Superinvestor 13F holdings · Analyst sentiment · Market valuation